Results 21 to 30 of about 57,705 (278)

Possibilities of immunogistochemical investigation in respons prognosis to treatment and modification of treatment activities at luminal breast cancer (literature review).

Medičnì Perspektivi, 2017
This article is concerned with both standard (estrogen and progesterone receptors, Her2/neu and Ki67) immu­nohistochemical investigation in hormonal therapy tactics decision for luminal breast cancer and additional in­vestigation of such hormonal ...
I. M. Bondarenko, V. F. Zavizion, M. V. Artemenko, M. I. Hojouj, L. O. Maltseva, І. V. Bilenkyi, V. А. Hurtovyi, V. V. Lohvynenko, A. V. Prokhach   +8 more
doaj   +1 more source

Managing menopausal symptoms and associated clinical issues in breast cancer survivors [PDF]

, 2017
Objective: Review evidence to guide management of menopausal signs and symptoms in women after breast cancer and make recommendations accordingly. Evidence: Randomized controlled clinical trials, observational studies, evidence-based guidelines, and
Davis, Susan R., Gompel, Anne, Lumsden, Mary Ann, Pinkerton, JoAnn V., Santen, Richard J., Stuenkel, Cynthia A.   +5 more
core   +1 more source

New 1,2,3-Triazole/1,2,4-triazole Hybrids as Aromatase Inhibitors: Design, Synthesis, and Apoptotic Antiproliferative Activity

Molecules, 2023
A novel series of 1,2,3-triazole/1,2,4-triazole hybrids 5a, 5b, and 6a–i was designed and synthesized as antiproliferative agents targeting aromatase enzymes.
Mohamed T-E Maghraby, Tahani Mazyad Almutairi, Stefan Bräse, Ola I. A. Salem, Bahaa G. M. Youssif, Mahmoud M. Sheha   +5 more
doaj   +1 more source

Decreased risk of breast cancer associated with oral bisphosphonate therapy [PDF]

, 2012
Preclinical studies and adjuvant trials using bisphosphonates have found them to have an antitumor effect. Although major advances have been made in chemoprevention strategies with selective estrogen receptor modulators and aromatase inhibitors, their ...
Brufsky, A, Mathew, A
core   +2 more sources

Aromatase inhibitors and antiepileptic drugs: a computational systems biology analysis

Reproductive Biology and Endocrinology, 2011
Background The present study compares antiepileptic drugs and aromatase (CYP19) inhibitors for chemical and structural similarity. Human aromatase is well known as an important pharmacological target in anti-breast cancer therapy, but recent research ...
Mustata Gabriela, Muftuoglu Yagmur
doaj   +1 more source

Locally Advanced Breast Cancer Patient’s Recurrence Rates Comparison Received Steroidal and Nonsteroidal Aromatase Inhibitor Based on Luminal

Biomolecular and Health Science Journal
Introduction: Aromatase inhibitors are hormonal therapies used in menopausal breast cancer with positive progesterone receptors and/or estrogen receptors.
Desak Gede Agung Suprabawati, Bernadeta Hernik Setiyandari, Dwi Hari Susilo, Bara Kharisma, Rizki Amalia   +4 more
doaj   +1 more source

A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility

Asian Journal of Andrology, 2020
Aromatase activity has commonly been associated with male infertility characterized by testicular dysfunction with low serum testosterone and/or testosterone to estradiol ratio.
Francesco Del Giudice, Gian Maria Busetto, Ettore De Berardinis, Isabella Sperduti, Matteo Ferro, Martina Maggi, Martin S Gross, Alessandro Sciarra, Michael L Eisenberg   +8 more
doaj   +1 more source

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer [PDF]

, 2015
Introduction Aromatase inhibitors (AIs) are a vital component of estrogen receptor positive (ER+) breast cancer treatment. De novo and acquired resistance, however, is common.
A Mackay, AK Dunbier, AK Dunbier, Alan Mackay, Alexey Larionov, Anita K Dunbier, Aradhana Rani, Ash Nerurkar, B Weigelt, BP Coe, C Curtis, C Kent, D Generali, DG Albertson, DS Tan, Elena López-Knowles, F Kreisel, Helen Anderson, HW Cheung, IE Smith, IE Smith, J Hicks, J Michael Dixon, Jorge S Reis-Filho, JS Foster, K Lundgren, L Osterberg, LA Martin, LA Martin, LA Martin, Lesley-Ann Martin, LG Leon, Lorna Renshaw, M Dowsett, M Mello-Grand, M Scaltriti, Mitch Dowsett, MJ Ellis, MT Weigel, N Turner, P Darbre, P Lal, Paul M Wilkerson, Peter Osin, PM Wilkerson, PM Wilkerson, PT Simpson, R Beroukhim, R Duprez, R Katz-Brull, R Natrajan, R Natrajan, R Natrajan, Ricardo Ribas, T Miyake, T Troiani, TK Lam, William R Miller, WR Miller, WR Miller, WR Miller, WR Miller, X Huo, Y Zhao, Z Ghazoui, Zara Ghazoui   +65 more
core   +3 more sources

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. [PDF]

, 2013
IntroductionEffective treatments for hormone-receptor-positive (HR(+)) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data
Arena, Francis P, Baselga, José, Burris, Howard A, Cahana, Ayelet, Campone, Mario, Erdkamp, Frans, Feng, Wentao, Gnant, Michael, Harb, Wael A, Hortobagyi, Gabriel N, Lebwohl, David, Melichar, Bohuslav, Noguchi, Shinzaburo, Petrakova, Katarina, Piccart, Martine, Pistilli, Barbara, Pritchard, Kathleen I, Rugo, Hope S, Taran, Tetiana, Yardley, Denise A   +19 more
core   +2 more sources

Depsidones inhibit aromatase activity and tumor cell proliferation in a co-culture of human primary breast adipose fibroblasts and T47D breast tumor cells

Toxicology Reports, 2017
Naturally occurring depsidones from the marine fungus Aspergillus unguis are known to have substantial anti-cancer activity, but their mechanism of action remains elusive. The purpose of this study was to examine the anti-aromatase activity of two common
Suthat Chottanapund, M.B.M. Van Duursen, Anne Zwartsen, Supatchaya Timtavorn, Panida Navasumrit, Prasat Kittakoop, Sanya Sureram, Mathuros Ruchirawat, Martin Van den Berg   +8 more
doaj   +1 more source